Joel Beatty

Stock Analyst at Baird

(4.62)
# 221
Out of 5,182 analysts
212
Total ratings
52.66%
Success rate
36.18%
Average return

Stocks Rated by Joel Beatty

Denali Therapeutics
Apr 7, 2026
Maintains: Outperform
Price Target: $32$34
Current: $19.45
Upside: +74.81%
Immutep
Mar 13, 2026
Downgrades: Neutral
Price Target: $7$1
Current: $0.57
Upside: +75.16%
Dianthus Therapeutics
Mar 10, 2026
Maintains: Outperform
Price Target: $67$132
Current: $89.82
Upside: +46.96%
Contineum Therapeutics
Mar 6, 2026
Maintains: Outperform
Price Target: $14$20
Current: $12.42
Upside: +61.03%
Praxis Precision Medicines
Feb 20, 2026
Maintains: Outperform
Price Target: $275$433
Current: $329.60
Upside: +31.37%
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Outperform
Price Target: $72$47
Current: $24.28
Upside: +93.57%
Jazz Pharmaceuticals
Nov 18, 2025
Maintains: Outperform
Price Target: $160$209
Current: $199.96
Upside: +4.52%
e.l.f. Beauty
Nov 6, 2025
Maintains: Outperform
Price Target: $145$125
Current: $66.23
Upside: +88.74%
Amylyx Pharmaceuticals
Oct 16, 2025
Maintains: Outperform
Price Target: $10$19
Current: $17.32
Upside: +9.70%
Larimar Therapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $10$7
Current: $4.50
Upside: +55.56%
Maintains: Outperform
Price Target: $4$6
Current: $3.21
Upside: +86.92%
Maintains: Neutral
Price Target: $7$9
Current: $36.14
Upside: -75.10%
Maintains: Outperform
Price Target: $28$31
Current: $22.11
Upside: +40.21%
Downgrades: Neutral
Price Target: $38$24
Current: $26.95
Upside: -10.95%
Upgrades: Outperform
Price Target: $680
Current: $787.95
Upside: -13.70%
Maintains: Outperform
Price Target: $70$66
Current: $68.59
Upside: -3.78%
Maintains: Outperform
Price Target: $160$162
Current: $182.72
Upside: -11.34%
Maintains: Outperform
Price Target: $38$41
Current: $33.91
Upside: +20.91%
Maintains: Outperform
Price Target: $28$32
Current: $27.68
Upside: +15.61%
Initiates: Outperform
Price Target: $75
Current: $88.68
Upside: -15.43%
Maintains: Neutral
Price Target: $72$65
Current: $53.98
Upside: +20.41%
Maintains: Outperform
Price Target: $540$240
Current: $0.22
Upside: +108,990.91%
Downgrades: Neutral
Price Target: $4.5
Current: $1.50
Upside: +200.00%
Maintains: Outperform
Price Target: $24$25
Current: $16.57
Upside: +50.88%
Maintains: Outperform
Price Target: $32$28
Current: $21.00
Upside: +33.33%
Initiates: Outperform
Price Target: $16
Current: $1.38
Upside: +1,059.42%
Maintains: Outperform
Price Target: $4$1.25
Current: $1.66
Upside: -24.70%
Initiates: Outperform
Price Target: $44
Current: $1.26
Upside: +3,392.06%
Maintains: Outperform
Price Target: $60$58
Current: $74.40
Upside: -22.04%
Maintains: Outperform
Price Target: $18$24
Current: $30.70
Upside: -21.82%
Downgrades: Underperform
Price Target: $18
Current: $8.47
Upside: +112.51%
Maintains: Outperform
Price Target: $9$6
Current: $1.67
Upside: +259.28%
Upgrades: Neutral
Price Target: $36$28
Current: $10.35
Upside: +170.53%
Downgrades: Neutral
Price Target: $170$175
Current: $313.79
Upside: -44.23%
Downgrades: Neutral
Price Target: $14
Current: $6.69
Upside: +109.27%
Downgrades: Neutral
Price Target: $108
Current: $20.42
Upside: +428.89%
Maintains: Buy
Price Target: $80$78
Current: $74.09
Upside: +5.28%
Maintains: Buy
Price Target: $140$100
Current: $19.34
Upside: +417.06%
Maintains: Buy
Price Target: $480$120
Current: $14.59
Upside: +722.48%
Maintains: Buy
Price Target: $480$450
Current: $4.28
Upside: +10,414.02%
Upgrades: Buy
Price Target: n/a
Current: $1.91
Upside: -
Maintains: Buy
Price Target: $19$15
Current: $8.15
Upside: +84.05%
Upgrades: Neutral
Price Target: $14$11
Current: $16.34
Upside: -35.74%
Maintains: Buy
Price Target: $15$19
Current: $9.27
Upside: +104.96%